Aspergilosis pulmonar invasora en pacientes reumatológicos: presentación de dos casos / Invasive pulmonary aspergillosis in rheumatological patients: presentation of two cases

La aspergilosis pulmonar invasora (API) es una infección causada por hongos del género Aspergillus que afecta principalmente a pacientes inmunocomprometidos y corresponde a la forma más grave de aspergilosis. Se asocia a una alta morbi-mortalidad, siendo fundamental un diagnóstico y tratamiento oportuno. Las manifestaciones clínicas son inespecíficas, por lo que un estudio adecuado es importante para el diagnóstico, principalmente en pacientes con factores de riesgo poco habituales. En la actualidad se han establecido categorías diagnósticas que consideran factores del hospedero, laboratorio micológico tradicional y biomarcadores como galactomanano. Éstos, junto a la mejor comprensión e interpretación de las imágenes tomográficas permiten ofrecer un manejo adecuado. En este artículo, se presentan dos casos clínicos de API en pacientes reumatológicos, y se discute la utilidad de los métodos diagnósticos.

Invasive pulmonary aspergillosis (IPA) is an infection caused by fungi of the genus Aspergillus that mainly affects immunocompromised patients and corresponds to the most severe form of aspergillosis. It is associated with high morbidity and mortality, and diagnosis and timely treatment are essential. Clinical manifestations are nonspecific, so an adequate study is important for diagnosis, mainly in patients with unusual risk factors. At present, diagnostic categories have been established that consider factors of the host, traditional mycological laboratory and biomarkers such as galactomannan. These, together with the better understanding and interpretation of the tomographic images, allow us to offer an adequate management. In this article, two clinical cases of API in rheumatological patients are presented, and the usefulness of the diagnostic methods is discussed.

Visión histórica de la Sociedad Chilena de Enfermedades Respiratorias en sus 85 años / Historic sight of the Chilean Society of Respiratory Diseases in its 85th anniversary

The Chilean Society of Respiratory Diseases was founded in 1930. It was initially named as "Society of Tisiology" since tuberculosis was a major health problem at that time. From then on, its development has mirrored the changes that Chilean society and medical sciences have undergone during XX and XXI centuries. Nowadays, the Chilean Society of Respiratory Diseases embraces distinct disciplines and types of health professionals, maintaining its involvement in clinical and public health issues. This review mentions the pioneers of Respiratory Medicine in Chile, as well as some of the most relevant actors, institutions and activities that have been developed by our society during its 85 years of existence.

La Sociedad Chilena de Enfermedades Respiratorias fue fundada en 1930. Inicialmente fue denominada "Sociedad Chilena de Fisiología" ya que en esa época la Tuberculosis era un problema crucial de salud. Desde entonces el desarrollo de la Sociedad ha reflejado los cambios que han experimentado la sociedad chilena y las ciencias médicas en el siglo XX y en los inicios del siglo XXI. Actualmente la Sociedad Chilena de Enfermedades Respiratorias abarca diversas disciplinas y profesionales de la salud, manteniendo su compromiso con temas clínicos y de salud pública. Este artículo menciona a los fundadores de la Medicina Respiratoria en Chile, como también a los actores, instituciones y actividades más relevantes que se han desarrollado en nuestra Sociedad durante sus 85 años de existencia.

Estudio multicéntrico de factores pronósticos en adultos hospitalizados por neumonía adquirida en la comunidad / Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients

Background: Severity assessment of community-acquired pneumonia (CAP) patients allows the clinician to decide the place of management and guide empirical antimicrobial treatment. Aim: To assess admission prognostic factors and outcome of CAP in immunocompetent adult patients hospitalized in 21 medical centers in Chile. Material and methods: Prospective evaluation of non immunocompromised adults with CAP admitted to 21 Chilean hospitals between July and August, 1999. All patients were assessed on admission and followed until discharge or death. Results: During the study period, 1,194 patients (aged 68±17 years, 573 males) were evaluated. Seventy two percent had an underlying disease (especially chronic cardiovascular, neurological, respiratory diseases and diabetes mellitus), and 90 percent were treated with ß-lactamic agents (especially a third generation cephalosporin or penicillin). Mean hospital length of stay was 11±9 days, 10 percent were admitted to Intermediate Care or Intensive Care Units (ICU), 6 percent were mechanically ventilated and in-hospital mortality was 15.7 percent. Admission prognostic factors associated with hospital mortality were: advanced age, male gender, presence of comorbidity (chronic cardiovascular, renal, neurological and hepatic disease), undernutrition, suspicion of aspiration, altered mental status, low blood pressure, tachypnea, absence of fever, high blood urea nitrogen, multilobar radiographic pulmonary infiltrates, high risk categories from Chilean Respiratory Diseases Society Consensus, admission to Intermediate Care Units or ICU, and mechanical ventilation. In the multivariate analysis, prognostic factors associated with high hospital mortality were: mental confusion, high blood urea nitrogen, multilobar pneumonia, presence of comorbidity and absence of fever on admission. Conclusions: These results validate in Chile, findings from foreign studies.

[Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients]. / Estudio multicéntrico de factores pronósticos en adultos hospitalizados por neumonía adquirida en la comunidad.

BACKGROUND: Severity assessment of community-acquired pneumonia (CAP) patients allows the clinician to decide the place of management and guide empirical antimicrobial treatment. AIM: To assess admission prognostic factors and outcome of CAP in immunocompetent adult patients hospitalized in 21 medical centers in Chile. MATERIAL AND METHODS: Prospective evaluation of non immunocompromised adults with CAP admitted to 21 Chilean hospitals between July and August, 1999. All patients were assessed on admission and followed until discharge or death. RESULTS: During the study period, 1,194 patients (aged 68+/-17 years, 573 males) were evaluated. Seventy two percent had an underlying disease (especially chronic cardiovascular, neurological, respiratory diseases and diabetes mellitus), and 90% were treated with beta-lactamic agents (especially a third generation cephalosporin or penicillin). Mean hospital length of stay was 11+/-9 days, 10% were admitted to Intermediate Care or Intensive Care Units (ICU), 6% were mechanically ventilated and in-hospital mortality was 15.7%. Admission prognostic factors associated with hospital mortality were: advanced age, male gender, presence of comorbidity (chronic cardiovascular, renal, neurological and hepatic disease), undernutrition, suspicion of aspiration, altered mental status, low blood pressure, tachypnea, absence of fever, high blood urea nitrogen, multilobar radiographic pulmonary infiltrates, high risk categories from Chilean Respiratory Diseases Society Consensus, admission to Intermediate Care Units or ICU, and mechanical ventilation. In the multivariate analysis, prognostic factors associated with high hospital mortality were: mental confusion, high blood urea nitrogen, multilobar pneumonia, presence of comorbidity and absence of fever on admission. CONCLUSIONS: These results validate in Chile, findings from foreign studies.

[Prevention of community-acquired pneumonia in adults]. / Prevención de la neumonía del adulto adquirida en la comunidad.

Polysaccharide 23 valent pneumococcal vaccine commercially available from 1983 includes 23 serotypes of Streptococcus pneumoniae, representing near 90% of strains involved in invasive pneumococcal disease in immune competent adults. Vaccine confers protection against invasive pneumococcal disease. Immunization is recommended in adults over 65 years old, in patients affected by chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage in brain-blood barrier, functional or anatomical asplenia, alcoholism), in immunocompromised hosts, including HIV infection, chemotherapy treatment and hematological malignancies. Influenza vaccine is prepared with particulated antigens, including two influenza A strains and one influenza B strain, selected according to influenza epidemiological worldwide surveillance the year before. On account of continuous antigenic changes (drifts), it is necessary to modify the vaccine antigen's composition yearly. Cost/effectiveness evaluation has confirmed the efficacy of influenza vaccine in reducing morbidity and mortality associated to influenza epidemic and health economical resources involved in patient care. Besides, clinical trials have confirmed that immunization reduces the risk of acquiring pneumonia, of hospitalization and death in elderly people during the influenza epidemic, when vaccine antigenic composition is similar to the circulating strains. Vaccination is recommended annually in healthy adults over 65 years old, in patients with chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage of blood-brain barrier, functional or anatomical asplenia, alcoholism). It is also recommended in women who will be in the second or third trimester of pregnancy during the influenza season, in immunocompromised hosts, in institutionalized patients (geriatrics), health care workers, and travelers to geographical areas that are affected by the influenza epidemic.

Prevención de la neumonía adquirida en la comunidad / Prevention o commmunity-acquired pneumonia in adutts

Polysaccharide 23 valent pneumococcal vaccine commercially available from 1983 includes 23 serotypes of Streptococcus pneumoniae, representing near 90% of strains involved in invasive pneumococcal disease in immune competent adults. Vaccine confers protection against invasive pneumococcal disease. Immunization is recommended in adults over 65 years old, in patients affected by chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage in brain-blood barrier, functional or anatomical asplenia, alcoholism), in immunocompromised hosts, including HIV infection, chemotherapy treatment and hematological malignancies. Influenza vaccine is prepared with particulated antigens, including two influenza A strains and one influenza B strain, selected according to influenza epidemiological worldwide surveillance the year before. On account of continuous antigenic changes (drifts), it is necessary to modify the vaccine antigen's composition yearly. Cost/effectiveness evaluation has confirmed the efficacy of influenza vaccine in reducing morbidity and mortality associated to influenza epidemic and health economical resources involved in patient care. Besides, clinical trials have confirmed that immunization reduces the risk of acquiring pneumonia, of hospitalization and death in elderly people during the influenza epidemic, when vaccine antigenic composition is similar to the circulating strains. Vaccination is recommended annually in healthy adults over 65 years old, in patients with chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage of blood-brain barrier, functional or anatomical asplenia, alcoholism). It is also recommended in women who will be in the second or third trimester of pregnancy during the influenza season, in immunocompromised hosts, in institutionalized patients (geriatrics), health care workers, and travelers to geographical areas ...

La vacuna anti neumocóccica polivalente disponible desde 1983 incluye 23 serotipos de Streptococcus pneumoniae, que representan cerca de 90% de las cepas que ocasionan enfermedad neumocóccica invasora en adultos inmunocompetentes. La vacuna confiere protección contra la enfermedad neumocóccica invasora. Se recomienda vacunar a los adultos sanos sobre 65 años de edad, portadores de enfermedades crónicas (cardiopatías, EPOC, nefropatías, diabetes mellitus, cirrosis hepática, pérdida crónica de LCR, asplenia funcional o anatómica, alcoholismo), inmunocomprometidos incluyendo los infectados por VIH, quimioterapia y neoplasias hematológicas. La vacuna anti influenza se prepara con antígenos particulados, e incluye dos tipos antigénicos de virus influenza A y una de influenza B, seleccionados de acuerdo al perfil epidemiológico que arroja la vigilancia mundial de influenza en el año anterior. Debido al cambio antigénico que se produce cada año, es necesario modificar la composición de la vacuna. Los estudios de costo-efectividad han confirmado la eficacia de la vacuna anti influenza en reducir la morbimortalidad asociada a la epidemia de influenza y los gastos de salud involucrados en el manejo de los enfermos. Además, los estudios clínicos han confirmado que la vacunación reduce el riesgo de neumonía, hospitalización y muerte en la población senescente durante la epidemia de influenza, cuando la cepa de la vacuna es similar a la presente en la comunidad. Se recomienda vacunar anualmente a los adultos sanos sobre 65 años de edad, portadores de enfermedades crónicas (cardiopatías, EPOC, nefropatías, diabetes mellitus, cirrosis hepática, pérdida crónica de LCR, asplenia funcional o anatómica, alcoholismo), mujeres embarazadas con más de 3 meses de gestación, inmunocomprometidos, pacientes institucionalizados (geriátricos, residentes en casas de reposo), trabajadores de la salud, viajeros a áreas geográficas de epidemia.